“Through multidisciplinary fusion”
New treatment developmen
What We Do
In response to unmet clinical needs, we bring together knowledge from various fields such as clinical medicine, basic medicine, pharmacology, engineering, and computational science.
We aim to develop new treatments through multidisciplinary fusion.
Emerging Medicine for Integrated Therapeutics
Aiming to contribute to the advancement of medical care and the promotion of health, we are engaged in not only basic research, but also translational and clinical research. In response to unmet clinical needs, we bring together knowledge from various fields such as clinical, basic, pharmaceutical, engineering, and computational science, regardless of field or method, and collaborate with experts to develop new treatments through multidisciplinary fusion. We are conducting research with the goal of development.
Aiming for antitumor treatment through epigenetic regulation
Targeting refractory hematopoietic tumors (multiple myeloma, acute T-lymphoblastic leukemia, mantle cell lymphoma) for which existing treatments are not sufficiently effective, we aim to elucidate the mechanism of hematopoietic tumor development and investigate tumor growth.・We are analyzing the control mechanisms of differentiation, cell death, and drug resistance from the perspective of epigenetics. As part of our research to develop therapeutic applications, we are also working on the development of therapeutic agents that target epigenetic abnormalities in joint research with RIKEN.
Biomarkers / Antiviral immunity / Antitumor immunity / Aiming to develop new immunotherapy
Targeting refractory hematopoietic tumors (multiple myeloma, acute T-lymphoblastic leukemia, mantle cell lymphoma) for which existing treatments are not sufficiently effective, we aim to elucidate the mechanism of hematopoietic tumor development and investigate tumor growth.・We are analyzing the control mechanisms of differentiation, cell death, and drug resistance from the perspective of epigenetics. As part of our research to develop therapeutic applications, we are also working on the development of therapeutic agents that target epigenetic abnormalities in joint research with RIKEN.
Aiming for optimal allogeneic hematopoietic cell transplantation depending on the patient
Targeting refractory hematopoietic tumors (multiple myeloma, acute T-lymphoblastic leukemia, mantle cell lymphoma) for which existing treatments are not sufficiently effective, we aim to elucidate the mechanism of hematopoietic tumor development and investigate tumor growth.・We are analyzing the control mechanisms of differentiation, cell death, and drug resistance from the perspective of epigenetics. As part of our research to develop therapeutic applications, we are also working on the development of therapeutic agents that target epigenetic abnormalities in joint research with RIKEN.
